Pricing Log in Create free account

IMMURON (IMRN) vs Karyopharm Therapeutics Inc. (KPTI)

IMMURON and Karyopharm Therapeutics Inc. are both Biotechnology companies. IMMURON and Karyopharm Therapeutics Inc. are of similar size ($8.3M and $8.0M). Karyopharm Therapeutics Inc. grew revenue faster over the last twelve months: 6.81% against −6.62%. Karyopharm Therapeutics Inc. has the higher net margin (−153.3% vs −262.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, IMMURON leads on 9 and Karyopharm Therapeutics Inc. on 6.

Valuation

Metric IMRN KPTI Biotechnology median
P/E n/m n/m 8.50
P/S n/m 0.08 9.71
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.93 n/m 0.64
EV/Sales (3.47) 1.34 9.21
Earnings yield (2.10%) (3,634.56%) (33.15%)
Free cash flow yield 0.00% (580.28%) (25.50%)

Profitability

Metric IMRN KPTI Biotechnology median
Gross margin 71.28% 95.89% 65.16%
Operating margin 0.00% (56.17%) 0.00%
Net margin (262.71%) (153.28%) 0.00%
Free cash flow margin 0.00% (44.57%) 0.00%
Return on equity 0.00% 78.98% (56.36%)
Return on assets 0.00% (207.90%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IMRN KPTI Biotechnology median
Revenue growth (TTM) (6.62%) 6.81% 6.02%
EPS growth (last fiscal year) 37.29% (98.37%) 30.26%
Revenue growth, 5-year CAGR 116.96% 6.21% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMRN KPTI Biotechnology median
Debt to equity 0.00 (0.76) 0.00
Current ratio 7.17 0.79 4.72
Net debt to EBITDA 1.81 (2.03) 0.96

Dividend

Metric IMRN KPTI Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric IMRN KPTI Biotechnology median
Market cap 8.31m 7.95m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack